Novo A/S has announced an expansion of its large investment portfolio through an investment in ERT alongside Nordic Capital Fund VIII. Plesner has acted as Novo A/S' legal advisor.

ERT is the leading provider of high-quality electronic data collection solutions for clinical drug development programmes. The company is headquartered in the US and its 1200 employees support more than 1500 clinical trials globally on an annual basis. The investment in ERT marks the expansion of Novo A/S' focus on its large investments to include the US.

Novo A/S and Nordic Capital have acquired the ownership of ERT from Genstar Capital, with Nordic Capital as the controlling shareholder. As long-term investor, Novo A/S - together with Nordic Capital - will provide significant backing for ERT to pursue a continued expansion of its activities.

Completion of the investment is subject to customary regulatory approvals.